Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen
(WorldNews Netherlands)

Genmab A/S Inside information Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen Company Announcement Copenhagen, Denmark; September 22, 2020 - Genmab A/S (Nasdaq: GMAB) announced today that it has commenced binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab. Under the license agreement, Genmab is, among other things, entitled to royalties from Janssen on sales of daratumumab (marketed as DARZALEX® for intravenous administration and, in the United States, as DARZALEX FASPRO™ for subcutaneous administration). The arbitration first is to settle whether Genmab is required to...